What is AskGene Pharma?
Founded in 2012 and headquartered in Los Angeles, California, AskGene Pharma is a specialized biotechnology firm focused on the discovery and development of novel antibody and fusion protein therapeutics. The company is best known for its proprietary SmartKine cytokine prodrug platform, which addresses critical challenges in the developability of cytokines for oncology and inflammation indications. By engineering prodrugs that improve therapeutic windows, AskGene is effectively mitigating the systemic toxicity often associated with traditional cytokine therapies. Their market position is bolstered by a robust intellectual property portfolio and a clear focus on high-unmet-need therapeutic areas, positioning them as a key innovator in the global biopharma ecosystem.
How much funding has AskGene Pharma raised?
AskGene Pharma has raised a total of $20.4M across 2 funding rounds:
Debt
$350K
Series A
$20M
Debt (2020): $350K with participation from PPP
Series A (2022): $20M led by TF Capital and Qiming Venture Partners
Key Investors in AskGene Pharma
TF Capital
TF Capital is a leading investor focused on partnering with early-stage innovators in the biotech sector, providing comprehensive capital and strategic expertise to support global growth.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that focuses on investing in innovative companies across technology and healthcare, offering industry resources and strategic guidance.
PPP
Public-Private Partnership
What's next for AskGene Pharma?
With the recent influx of capital, AskGene Pharma is strategically positioned to advance its lead candidates through the rigorous phases of clinical and preclinical development. The primary objective for the upcoming fiscal periods involves scaling the SmartKine platform to support a broader range of oncology and inflammation projects. Furthermore, the company is expected to leverage its investor network to facilitate potential licensing agreements and strategic partnerships, which are essential for navigating the complex regulatory and commercialization pathways in the United States and international markets. As the firm moves deeper into clinical trials, the focus will shift toward demonstrating efficacy and safety profiles that justify the significant investment received to date.
See full AskGene Pharma company page
